Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more severe disease Patients with prior anti-VEGF treatment and switched to UBX1325 monotherapy at study start maintained visual acuity through 24 weeks and had only a 1.5 letter decrease from baseline at week 48 40% of UBX1325-treated patients did not require anti-VEGF treatment through 48 weeks and 64% achieved an anti-VEGF treatment-free interval of over 24 weeks UBX1325 was well tolerated in both monotherapy and combination arms SOUTH SAN FRANCISCO, Calif., Sept.

从第24-48周开始与UBX1325和阿柏西普联合治疗的患者在第24周单独使用阿柏西普维持视力增加，随着更严重疾病患者的视力改善，先前接受抗VEGF治疗并在研究开始时改用UBX1325单药治疗的患者在24周内保持视力，并且在48周时仅比基线降低1.5个字母40%的UBX1325治疗患者在48周内不需要抗VEGF治疗，64%达到无抗VEGF治疗超过24周的间隔UBX1325在单一疗法和联合疗法中均具有良好的耐受性，南旧金山，加利福尼亚州，9月。

27, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced results from Part B of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum benefit with their ongoing anti-VEGF therapy.

272023年（GLOBE NEWSWIRE）-UNITY Biotechnology，Inc。（“UNITY”）[Nasdaq:UBX]，一家开发减缓，阻止或逆转衰老疾病治疗药物的生物技术公司，今天宣布B部分的结果。UBX1325在湿性年龄相关性黄斑变性（AMD）患者中的第2阶段ENVISION研究，这些患者在正在进行的抗VEGF治疗中未获得最佳益处。

UBX1325 demonstrated a favorable safety and tolerability profile in the combination and monotherapy arms with no cases of significant intraocular inflammation, retinal artery occlusion or endophthalmitis. Patients switched from every 8-week aflibercept to a combination of aflibercept and UBX1325 at week 24 maintained vision gains achieved with aflibercept alone through week 48.

UBX1325在联合治疗组和单药治疗组中表现出良好的安全性和耐受性，没有明显的眼内炎症，视网膜动脉闭塞或眼内炎的病例。在第24周时，患者从每8周一次阿柏西普转换为阿柏西普和UBX1325的组合，在第48周时单独使用阿柏西普维持视力增加。

Patients in a pre-specified subgroup with poor visual acuity at baseline (≤60 ETDRS letters) gained 3.2 ETDRS letters on combination treatment between weeks 24 and 48. In the UBX1325 monotherapy arm, patients maintained visual acuity for the duration of the study, with a mean change of +0.1 ETDRS letters at the 24-week time point and a mean change of -1.5 ETDRS.

在基线（≤60ETDRS字母）视力差的预先指定的亚组中，在第24周和第48周之间联合治疗获得3.2个ETDRS字母。在UBX1325单药治疗组中，患者在研究期间保持视力，在24周时间点平均变化+0.1 ETDRS字母，平均变化-1.5 ETDRS。